Ilumya (tildrakizumab) is a medication used to treat moderate to severe plaque psoriasis in adults. It is a prescription medicine administered as an injection.

Uses:

Ilumya is used to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

HOW TO USE:

Ilumya is administered as a subcutaneous injection by a healthcare provider. The injection should be given every 12 weeks after the initial doses.

Dosage:

The recommended dosage of Ilumya is 100 mg every 12 weeks, following an initial dose of 200 mg. The dosage may be adjusted based on the response of the patient.

Mechanism of Action:

Ilumya inhibits the activity of a protein called interleukin 23 (IL-23). This reduces inflammation, which is the underlying cause of psoriasis. This action of Ilumya helps relieve the symptoms of psoriasis.

Storage Conditions:

Ilumya should be refrigerated at 2°C to 8°C and protected from light.

Precautions:

• Ilumya may increase the risk of infection. Patients should inform their healthcare provider of any signs or symptoms of an infection such as fever, cough, or flu-like symptoms while taking Ilumya.
• Patients should not receive live vaccines while taking Ilumya.
• There is a risk of allergic reaction to Ilumya, and patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling of the face or throat, or rash.

Interactions:

• Ilumya has not been studied in combination with other systemic therapies for psoriasis. Patients should inform their healthcare provider of all medications they are taking before starting treatment with Ilumya.

Contraindications:

• Ilumya is contraindicated in patients who have a known hypersensitivity to tildrakizumab or any of its components.

Side Effects:

The most commonly reported side effects of Ilumya are upper respiratory tract infections, headache, injection site reactions, and diarrhea. Serious adverse events reported include infections such as tuberculosis and allergic reactions. Patients should inform their healthcare provider of any unusual symptoms while taking Ilumya.

Overdose:

No cases of overdose have been reported with Ilumya.

In conclusion, Ilumya (tildrakizumab) is a medication used to treat moderate to severe plaque psoriasis in adults. The recommended dosage is 100 mg every 12 weeks, after an initial dose of 200 mg. Ilumya works by inhibiting the activity of IL-23, a protein responsible for inflammation, which relieves the symptoms of psoriasis. Ilumya should be refrigerated and protected from light and is contraindicated in patients who have a hypersensitivity to tildrakizumab or any of its components. Patients should inform their healthcare provider of any signs or symptoms of infection while taking Ilumya, and they should not receive live vaccines. The most common side effects of Ilumya include upper respiratory tract infections, headache, injection site reactions, and diarrhea, and allergic reactions can occur. There is no reported case of an overdose of Ilumya.